Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Risk stratification of MGUS

Vincent Rajkumar • 16 May 2019
COMy 2019
Multiple Myeloma

Monoclonal gammopathy of unknown significance effects 3-4% of the general population, 50 years of age and above. Vincent Rajkumar, MD from the Mayo Clinic, Rochester, MN, presents methods to stratify the risk of disease progression to multiple myeloma. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Vincent Rajkumar

2:04
Lenalidomide for smoldering myeloma
Vincent Rajkumar • 17 May 2019
3:20
Is there potential to reduce the cost of myeloma therapy?
Vincent Rajkumar • 17 May 2019
Characterization of exceptional responders to ASCT in multiple myeloma
Vincent Rajkumar • 6 Dec 2018
Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar • 2 Dec 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals